Business
Positive progress on European Patent Application
Positive progress on European Patent Application.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\n 26 March 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nPositive progress on European Patent Application for the AWKN-SDN-14 programme\n \nSolvonis Therapeutics plc (LSE: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to report a positive development in the intellectual property position of the AWKN-SDN-14 programme (the \"Programme\"), its collaboration with Awakn Life Sciences Corp. (\"Awakn\"). The collaboration is focused on developing next-generation medicine for the treatment of trauma-related mental health disorders, such as Post-Traumatic Stress Disorder (\"PTSD\"), which affects approximately 13 million adults in the U.S. and which the Company estimates affects 20 million in the US, the UK, and other key EU markets.\nFollowing the Company's announcement on 22 March 2025 regarding preclinical progress and the appointment of Evotec SE to lead in-vitro testing, the European Patent Office (the \"EPO\") has confirmed that the claims under European Patent Application No. 22730070.4, titled \"Therapeutic Aminoindane Compounds and Compositions\", are considered allowable with no objections.\nThis application is one of two patent families underpinning the Programme's intellectual property portfolio and specifically covers key compound classes being advanced through preclinical development. It represents the European leg of a broader international patent strategy for the Programme, with protection also being pursued in other key jurisdictions, including the United States.\nIn line with standard EPO procedure, the patent examiner has requested a minor amendment to the description to reflect the scope of the allowed claims. Subject to this formality, the application is expected to proceed to grant.\nThis development provides strong validation of the novelty and inventiveness of the Programme's core compounds and further strengthens its intellectual property position across Europe.\nAnthony Tennyson, CEO of Solvonis Therapeutics, commented: \"This positive news from the European Patent Office is a strong validation of the scientific and commercial potential of the AWKN-SDN-14 programme. Robust intellectual property is a critical pillar of our and Awakn's strategy, and this progress represents an important step forward as we conti...